OTCMKTS:IPHYFInnate Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Innate Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.23 0.00 (0.00 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$6.23Now: $6.23▼$6.2350-Day Range$4.90MA: $6.40▼$7.0752-Week Range$3.70Now: $6.23▼$8.12VolumeN/AAverage Volume594 shsMarket Capitalization$489.30 millionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsHeadlinesSocial Media Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. It offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase I clinical trial for cutaneous T-cell lymphomas; Monalizumab, a checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications, as well as in Phase I/II clinical trial for the treatment of solid tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. The company also provides Lirilumab (IPH2102/BMS-986015), a human monoclonal antibody that blocks the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands; IPH52, an anti-CD39 antibody for immuno-oncology; IPH53, an anti-CD73 antibody for immuno-oncology; and IPH4301, an anti-MICA/B therapeutic antibody to treat oncology. In addition, it offers a commercial-stage product, Lumoxiti, an oncology product for treating hairy cell leukemia. The company has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi. Innate Pharma S.A. has a clinical trial collaboration with MedImmune. The company was founded in 1999 and is based in Marseille, France.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingInnate Pharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Innate Pharma has a potential upside of 76.6% from its current price of $6.23.Amount of Analyst CoverageInnate Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesInnate Pharma has received 125 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInnate Pharma has received 99 “underperform” votes. (Add your “underperform” vote.)Community SentimentInnate Pharma has received 55.80% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote “Outperform” if you believe IPHYF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IPHYF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInnate Pharma does not currently pay a dividend.Dividend GrowthInnate Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innate Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioInnate Pharma has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.21 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CUSIPN/A CIKN/A Webwww.innate-pharma.com Phone33-4-30-30-30-30Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$96.12 million Price / Sales5.09 Cash FlowN/A Price / Cash FlowN/A Book Value$4.23 per share Price / Book1.47Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees195 Outstanding Shares78,540,000Market Cap$489.30 million Next Earnings Date6/9/2020 (Estimated) OptionableNot Optionable OTC:IPHYF Rates by TradingView Receive IPHYF News and Ratings via Email Sign-up to receive the latest news and ratings for IPHYF and its competitors with MarketBeat's FREE daily newsletter. Innate Pharma (OTCMKTS:IPHYF) Frequently Asked Questions How has Innate Pharma's stock been impacted by COVID-19 (Coronavirus)? Innate Pharma's stock was trading at $7.1690 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IPHYF shares have decreased by 13.1% and is now trading at $6.23. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Innate Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innate Pharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innate Pharma. When is Innate Pharma's next earnings date? Innate Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, June 9th 2020. View our earnings forecast for Innate Pharma. What price target have analysts set for IPHYF? 2 brokerages have issued 12 month price objectives for Innate Pharma's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Innate Pharma's stock price to reach $11.00 in the next year. This suggests a possible upside of 76.6% from the stock's current price. View analysts' price targets for Innate Pharma. Has Innate Pharma been receiving favorable news coverage? News stories about IPHYF stock have been trending somewhat positive recently, according to InfoTrie. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Innate Pharma earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutInnate Pharma. Who are some of Innate Pharma's key competitors? Some companies that are related to Innate Pharma include Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), Twist Bioscience (TWST), I-Mab (BDTX), Mesoblast (MESO), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Cortexyme (CRTX), Translate Bio (TBIO), NanoString Technologies (NSTG) and Proteon Therapeutics (PRTO). View all competitors. Who are Innate Pharma's key executives? Innate Pharma's management team includes the following people: Dr. Hervé Brailly, Co-Founder & Chairman of Supervisory Board (Age 58)Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (Age 61)Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (Age 46)Ms. Laure-Hélène Mercier, Exec. VP, CFO & Member of Exec. Board (Age 41)Mr. Eric Vivier D.V.M., Ph.D., Sr. VP & Chief Scientific Officer (Age 55) What is Innate Pharma's stock symbol? Innate Pharma trades on the OTCMKTS under the ticker symbol "IPHYF." How do I buy shares of Innate Pharma? Shares of IPHYF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Innate Pharma's stock price today? One share of IPHYF stock can currently be purchased for approximately $6.23. How big of a company is Innate Pharma? Innate Pharma has a market capitalization of $489.30 million and generates $96.12 million in revenue each year. Innate Pharma employs 195 workers across the globe. What is Innate Pharma's official website? The official website for Innate Pharma is www.innate-pharma.com. How can I contact Innate Pharma? Innate Pharma's mailing address is 117 AVENUE DE LUMINY - BP 30191, MARSEILLE I0, 13009. The company can be reached via phone at 33-4-30-30-30-30 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
